- Home
- RYTM vs FBP Comparison
RYTM vs FBP Comparison
Compare RYTM & FBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RYTM
- FBP
- Stock Information
- Founded
- RYTM 2008
- FBP 1948
- Country
- RYTM United States
- FBP United States
- Employees
- RYTM N/A
- FBP N/A
- Industry
- RYTM Biotechnology: Pharmaceutical Preparations
- FBP Major Banks
- Sector
- RYTM Health Care
- FBP Finance
- Exchange
- RYTM Nasdaq
- FBP Nasdaq
- Market Cap
- RYTM 3.1B
- FBP 3.4B
- IPO Year
- RYTM 2017
- FBP N/A
- Fundamental
- Price
- RYTM $59.03
- FBP $21.03
- Analyst Decision
- RYTM Strong Buy
- FBP Buy
- Analyst Count
- RYTM 10
- FBP 4
- Target Price
- RYTM $62.30
- FBP $20.75
- AVG Volume (30 Days)
- RYTM 701.0K
- FBP 1.1M
- Earning Date
- RYTM 11-05-2024
- FBP 10-23-2024
- Dividend Yield
- RYTM N/A
- FBP 3.03%
- EPS Growth
- RYTM N/A
- FBP 9.82
- EPS
- RYTM N/A
- FBP 1.81
- Revenue
- RYTM $112,530,000.00
- FBP $868,818,000.00
- Revenue This Year
- RYTM $63.95
- FBP N/A
- Revenue Next Year
- RYTM $43.24
- FBP $5.15
- P/E Ratio
- RYTM N/A
- FBP $11.66
- Revenue Growth
- RYTM 81.55
- FBP N/A
- 52 Week Low
- RYTM $31.53
- FBP $14.72
- 52 Week High
- RYTM $68.58
- FBP $22.40
- Technical
- Relative Strength Index (RSI)
- RYTM 55.82
- FBP 54.30
- Support Level
- RYTM $55.37
- FBP $20.34
- Resistance Level
- RYTM $60.79
- FBP $22.15
- Average True Range (ATR)
- RYTM 3.60
- FBP 0.61
- MACD
- RYTM -0.27
- FBP 0.02
- Stochastic Oscillator
- RYTM 52.59
- FBP 61.19
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.
About FBP First BanCorp. New
First BanCorp is a financial holding company. The company's operating segment includes Commercial and Corporate Banking; Mortgage Banking; Consumer (Retail) Banking; Treasury and Investments; United States Operations; and Virgin Islands Operations. It generates maximum revenue from the Consumer (Retail) Banking segment. The Consumer (Retail) Banking segment generates majority revenue, which consists of the Corporation's consumer lending and deposit-taking activities conducted mainly through its branch network and loan centres. Geographically, it derives a majority of revenue from Puerto Rico.